A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia

Refractory Acute Leukemia Clinical Trial

Official title:
A Phase I and Pharmacodynamic Trial of Timed Sequential Administration of the Cyclin Dependent Kinase 4/6 Inhibitor PD 0332991 Followed by Cytarabine Plus Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasias

Status Terminated

Clinical Trial Summary

1.1 Primary Objectives

- To determine the feasibility, tolerability, and toxicities of administering the selective CDK 4/6 inhibitor PD 0332991 prior to the combination of ara-C and Mitoxantrone for adults with relapsed and refractory acute leukemias and high risk myelodysplasias (MDS), including primary refractory disease

- To determine the direct cytotoxic effects of single agent PD 0332991 on malignant blasts

- To determine the maximal tolerated dose (MTD) of PD 0332991 in timed sequential combination with ara-C and Mitoxantrone

- To determine if the timed sequential combination of PD 0332991 with ara-C and mitoxantrone can induce clinical responses in adults with relapsed or refractory acute leukemias and high-risk MDS

1.2 Secondary Objectives:

- To determine the ability of PD 0332991 to directly induce apoptosis in malignant cell populations in vivo

- To obtain pharmacodynamic (PD) data regarding the ability of PD 0332991 to arrest malignant cells in the G 1 phase of cell cycle, followed by synchronized release of those cells into S phase upon discontinuation of PD 0332991 and resultant enhanced ara-C cytotoxicity

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01701375
Study type	Interventional
Source	Sidney Kimmel Comprehensive Cancer Center
Contact
Status	Terminated
Phase	Phase 1
Start date	September 2012
Completion date	April 2013

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05029141` - New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia	Phase 2
Not yet recruiting	`NCT06397027` - A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias	Phase 1
Active, not recruiting	`NCT03834961` - Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia	Phase 2
Recruiting	`NCT00984412` - Allo-Allo Tandem Bone Marrow Transplant (BMT)	Phase 1/Phase 2
Active, not recruiting	`NCT04681105` - Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies	Phase 1
Completed	`NCT03735875` - Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia	Phase 1/Phase 2
Completed	`NCT00410423` - Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias	Phase 1/Phase 2
Not yet recruiting	`NCT06466395` - A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias	Phase 1